RO7268489

Phase 2Small molecule

Roche

RO7268489 is one of 3 small molecule programs targeting Progressive Multiple Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Progressive Multiple SclerosisRecruiting

Progressive Multiple SclerosisPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Progressive Multiple Sclerosis

#DrugCompanyPhaseTrials

Ocrevus

Roche

Phase 2

1 2

Rapcabtagene Autoleucel

Novartis

Preclinical

1 3

RO7268489

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

Progressive Multiple Sclerosis

NCT07282574

Clinical

Trials by Indication[1]

Progressive Multiple Sclerosis1 trial

A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis

Recruiting· Roche logo

Roche·Phase 2·NCT07282574·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RO7268489. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RO7268489 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RO7268489. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Roche

RO7268489

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Progressive Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News